Literature DB >> 11108795

Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability.

S O Jacobsson1, E Rongård, M Stridh, G Tiger, C J Fowler.   

Abstract

In the present study, the effects of the combination of tamoxifen ((Z)-2[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylamine citrate) and three cannabinoids (Delta(9)-tetrahydrocannabinol [Delta(9)-THC], cannabidiol, and anandamide [AEA]) upon the viability of C6 rat glioma cells was assessed at different incubation times and using different culturing concentrations of foetal bovine serum (FBS). Consistent with previous data for human glioblastoma cells, the tamoxifen sensitivity of the cells was increased as the FBS content of the culture medium was reduced from 10 to 0.4 and 0%. The cells expressed protein kinase C alpha and calmodulin (the concentration of which did not change significantly as the FBS concentration was reduced), but did not express estrogen receptors. Delta(9)-THC and cannabidiol, but not AEA, produced a modest reduction in cell viability after 6 days of incubation in serum-free medium, whereas no effects were seen in 10% FBS-containing medium. There was no observed synergy between the effects of tamoxifen and the cannabinoids upon cell viability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11108795     DOI: 10.1016/s0006-2952(00)00492-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 2.  Cannabidiol as potential anticancer drug.

Authors:  Paola Massi; Marta Solinas; Valentina Cinquina; Daniela Parolaro
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 3.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

4.  Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.

Authors:  Christopher Duntsch; Murali Krishna Divi; Terreia Jones; Qihong Zhou; Mathangi Krishnamurthy; Peter Boehm; George Wood; Allen Sills; Bob M Moore
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

5.  Cannabidiol Antiproliferative Effect in Triple-Negative Breast Cancer MDA-MB-231 Cells Is Modulated by Its Physical State and by IGF-1.

Authors:  Alessia D'Aloia; Michela Ceriani; Renata Tisi; Simone Stucchi; Elena Sacco; Barbara Costa
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

Review 6.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

7.  Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.

Authors:  Sean D McAllister; Calvin Chan; Ryan J Taft; Tri Luu; Mary E Abood; Dan H Moore; Ken Aldape; Garret Yount
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

Review 8.  Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.

Authors:  Eiron Cudaback; Nephi Stella
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

9.  Cannabinoid-induced autophagy regulates suppressor of cytokine signaling-3 in intestinal epithelium.

Authors:  Luan C Koay; Rachael J Rigby; Karen L Wright
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-15       Impact factor: 4.052

Review 10.  Critical appraisal of the potential use of cannabinoids in cancer management.

Authors:  Belinda J Cridge; Rhonda J Rosengren
Journal:  Cancer Manag Res       Date:  2013-08-30       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.